Next Article in Journal
Enhancing Perception with Tactile Object Recognition in Adaptive Grippers for Human–Robot Interaction
Next Article in Special Issue
Real-Time Tau Protein Detection by Sandwich-Based Piezoelectric Biosensing: Exploring Tubulin as a Mass Enhancer
Previous Article in Journal
Spatio-Temporal Analysis of Urban Acoustic Environments with Binaural Psycho-Acoustical Considerations for IoT-Based Applications
Previous Article in Special Issue
Microwave Sensors for Breast Cancer Detection
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessArticle
Sensors 2018, 18(3), 691;

Label-Free Quantification of Anti-TNF-α in Patients Treated with Adalimumab Using an Optical Biosensor

Evidence-Based Therapeutics Group, Clinical Pharmacology, Universidad de La Sabana, 140013 Chía, Colombia
Riesgo de Fractura S.A.-CAYRE, 110221 Bogotá, Colombia
Author to whom correspondence should be addressed.
Received: 5 December 2017 / Revised: 14 February 2018 / Accepted: 15 February 2018 / Published: 26 February 2018
(This article belongs to the Special Issue Label-Free Biosensors)
Full-Text   |   PDF [2932 KB, uploaded 26 February 2018]   |  


This study describes the development of an immunosensory label-free quantification methodology based on surface plasmon resonance (SPR) and its applicability in measuring/evaluating therapeutic drug monitoring (TDM) of anti-TNF-α monoclonal antibody (adalimumab) in rheumatoid arthritis (RA) patients. The experimental parameters evaluated in this study were immobilising ligands by pre-concentration assays, sensor surface regeneration, ascertaining the method’s sensitivity and correlating the results from quantifying plasma samples by ELISA immunoassay. The results showed that TNF-α quantification values (in RU) were significantly different when comparing patients (~50–250 RU) to controls (~10–20 RU). Likewise, there was 0.97 correlation for patients and 0.91 for healthy volunteers using SPR and ELISA comparison methodologies. SPR immunosensory detection provided a precise, sensitive strategy, along with real-time determination, for quantifying adalimumab, having great potential for clinical routine regarding TDM. View Full-Text
Keywords: biological drug; therapeutic drug monitoring (TDM); optical biosensor biological drug; therapeutic drug monitoring (TDM); optical biosensor

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Bustos, R.H.; Zapata, C.; Esteban, E.; García, J.-C.; Jáuregui, E.; Jaimes, D. Label-Free Quantification of Anti-TNF-α in Patients Treated with Adalimumab Using an Optical Biosensor. Sensors 2018, 18, 691.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Sensors EISSN 1424-8220 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top